Deerfield Management and Vanderbilt University have launched Ancora Innovation with $65m in capital to support early-stage life science research and back resulting spinouts.

Jointown Pharmaceutical Group and Lilly Asia Ventures were among the investors in the genetic sequencing technology developer's series A+ round.

Novartis, Eli Lilly and Amgen-backed cancer immunotherapy developer Surface Oncology has filed for a $75m offering on Nasdaq.

Biopharmaceuticals developer Aslan Pharmaceuticals, which counts AMT, Accuron and Tianda as backers, has filed to raise up to $86.3m in an initial public offering.

Alphabet subsidiaries Capital G and Verily Life Sciences took part in a round that took Oscar's total funding to $935m, valuing it at $3.2bn.

The WuXi PharmaTech-backed cancer treatment developer has received $50m in a round featuring another corporate investor, New World TMT.

Hua Medicine raised the funding in series D and E rounds, with the investors including WuXi AppTec, Ping An, Eight Roads and F-Prime Capital Partners.

Axcend hoppes to release a portable liquid chromatograph that has a high sensitivity and is compatible with various web-enabled devices.

NMD Pharma, a neuromuscular disorder-focused spinout from Aarhus University, secured $47m in a round co-led by Roche and backed by Novo and Lundbeck.